Overdose of Colofac/Colofac Retard in details
If too many tablets of Colofac/Colofac Retard is taken, contact a physician.
In cases where Colofac/Colofac Retard was taken in overdose, symptoms were either absent or mild and usually rapidly reversible.
On theoretical grounds, it may be predicted that central nervous system excitability will occur in cases of overdosage.
Observed symptoms of overdose were of neurological and cardiovascular nature. No specific antidote is known. Symptomatic treatment is recommended. Gastric lavage should only be considered in case of a severe overdosing which is discovered within about 1 hr. Absorption reducing measures are not necessary.
Colofac/Colofac Retard warnings
Use with caution in:
Hereditary blood disorders called porphyrias.
Certain medicines should not be used during pregnancy or breastfeeding. However, other medicines may be safely used in pregnancy or breastfeeding providing the benefits to the mother outweigh the risks to the unborn baby. Always inform your doctor if you are pregnant or planning a pregnancy, before using any medicine.
This medicine should be used with caution during pregnancy, and only if the expected benefit to the mother is greater than any possible risk to the foetus. Seek medical advice from your doctor.
This medicine passes into breast milk, but the amount is considered too small to be harmful to a nursing infant. Seek further medical advice from your doctor.
Keep all medicines out of the sight and reach of children.
Make sure that the person prescribing this medicine knows about any other medicines that you are taking. This includes medicines you buy and herbal and homeopathic medicines.
If you buy any medicines check with a pharmacist that they are safe to take with your other medicines.
Before taking this medicine tell your doctor if you have ever had an allergic reaction after taking any medicine.
Never take more than the prescribed dose. If you suspect that you or someone else has taken an overdose of this medicine go to the accident and emergency department of your local hospital at once. Always take the container with you, if possible, even if it is empty.
If you are having any treatment like an operation or dental treatment tell the person carrying out the treatment which medicines you are taking.
Always read the printed information leaflet that comes with your medicine.
This medicine is for you. Never give it to other people even if their condition appears to be the same as yours.
Never keep out of date or unwanted medicines. Take them to your local pharmacy which will dispose of them for you.
If you have any questions about this medicine ask your pharmacist.
Colofac/Colofac Retard precautions
Colofac/Colofac Retard: Based on theoretical concerns, it should be used with caution in patients with marked hepatic or renal impairment, and those with cardiac disorders eg, heart block.
Cystic Fibrosis: It was recommended that antispasmodics eg, mebeverine should not be used for the symptomatic treatment of distal intestinal syndrome in cystic fibrosis.
Porphyria: Mebeverine hydrochloride is considered to be unsafe in patients with porphyria because it has been shown to be porphyrinogenic in in vitro systems.
Colofac/Colofac Retard coated tablets contain lactose, if the patient has intolerance to lactose (or other types of sugar), contact the physician before taking Colofac/Colofac Retard.
Furthermore, the patient should not take Colofac/Colofac Retard if any of the following hereditary problems is present: Galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption.
The coating of the tablets contains sucrose. The patient should not take Colofac/Colofac Retard if any of the following hereditary problems is present: Fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency.
Effects on the Ability to Drive or Operate Machinery: No studies on the effects on the ability to drive and operate machines have been performed.
Colofac/Colofac Retard: The pharmacodynamic and pharmacokinetic profile, as well as post-marketing experience, do not indicate any harmful effect of mebeverine on the ability to drive or to use machines.
Impairment of Fertility: There is no clinical information on mebeverine’s influence on male or female fertility; however, animal studies do not indicate harmful effects.
Use in pregnancy: Colofac/Colofac Retard: Only a very limited amount of information on the use of mebeverine in pregnant women is available. Animal studies are insufficient with respect to reproductive toxicity. Do not take Colofac/Colofac Retard if pregnant.
Colofac/Colofac Retard Retard: Animal experiments have failed to show any teratogenic effects. However, the usual precautions concerning the administration of any drug during pregnancy should be observed.
Use in lactation: Colofac/Colofac Retard: It is unknown whether mebeverine or its metabolites is excreted in human milk. The excretion of mebeverine in milk has not been studied in animals. Do not take Colofac/Colofac Retard while breastfeeding.
Colofac/Colofac Retard Retard: Colofac/Colofac Retard Retard is not excreted in milk of lactating women after therapeutic doses.
Use in children: Colofac/Colofac Retard should not be used in children.
- DrugBank. "Mebeverine". http://www.drugbank.ca/drugs/DB12554 (accessed September 17, 2018).
- MeSH. "Parasympatholytics". https://www.ncbi.nlm.nih.gov/mesh/68... (accessed September 17, 2018).
There are no reviews yet. Be the first to write one!
Information checked by Dr. Sachin Kumar, MD Pharmacology